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Abstract 
Background: Since 2014, a considerable increase in Plasmodium vivax malaria has been observed in Germany. The 
majority of cases was seen in Eritrean refugees.
Methods: All patients with P. vivax malaria admitted to the University Medical Centre Hamburg-Eppendorf Germany 
from 2011 until August 2015 were retrospectively identified by the hospital coding system and data was matched 
with records from the laboratory diagnostics unit of the Bernhard Nocht Institute for Tropical Medicine, Hamburg, 
Germany.
Results: Between May 2014 and August 2015, 37 cases were reported in newly-arrived Eritrean refugees at the 
University Medical Centre Hamburg-Eppendorf, Germany. Relapses occurred due to difficulties in procurement of 
primaquine.
Conclusion: Countries hosting Eritrean refugees need to be aware of vivax malaria occurring in this group and the 
risk of autochthonous cases due to local transmission by indigenous, vector competent Anopheles species.
Keywords: Malaria, Plasmodium vivax, Refugees, Eritrea, Horn of Africa
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Around 500–600 annual cases of malaria were reported 
in Germany in the years before 2013. 80 % were Plasmo-
dium falciparum malaria, almost exclusively imported 
from West Africa [1]. Other forms of malaria were of 
minor importance (7  % vivax malaria in 2013). Since 
2014, this has changed dramatically: the number of 
reported malaria cases has almost doubled compared 
to the previous years [1] and clinicians are observing 
growing numbers of Plasmodium vivax infections, pre-
dominantly in refugees from Eritrea. Plasmodium vivax 
infections are characterized by relapses of malaria due to 
persistent liver stages of the parasite (hypnozoites). Those 
relapses can be prevented currently only by 8-aminoqui-
noline anti-malarials, such as primaquine [2].
In Europe, the number of asylum seekers status is con-
tinuously climbing with more than 200,000 applications 
in the European Union in 2014, most of them in Ger-
many [3, 4]. In the previous 2  years, there was a sharp 
increase in the number of refugees and migrants crossing 
the Mediterranean Sea, with the largest group coming 
from Eritrea and Syria [3, 5].
In this report, the impact of these recent migra-
tion trends on the epidemiology of malaria cases seen 
in a large referral and teaching hospital in Germany is 
described.
Methods
The study was performed at the University Medical Cen-
tre Hamburg-Eppendorf (UKE), a 1600-bed tertiary-care 
referral and teaching hospital with a specialist tropi-
cal medicine unit, in Hamburg, northern Germany. For 
tropical diseases the catchment area of this hospital is 
northern Germany. All patients admitted to the hospital 
with P. vivax malaria from 2011 until August 2015 were 
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retrospectively identified by the “International Statistical 
Classification of Diseases and Related Health Problems” 
(ICD) and matched the data with records from the labo-
ratory diagnostics unit of the Bernhard Nocht Institute 
for Tropical Medicine, Hamburg, which is the national 
reference laboratory for tropical pathogens in Germany. 
Diagnosis of malaria was performed by reading thin and 
thick blood films. In cases of low parasitaemia, blood was 
subjected to species-specific polymerase chain reaction 
(PCR) for species differentiation. The success of sub-
sequent primaquine therapy after initial anti-malarial 
chemotherapy was evaluated by telephone interviews of 
patients or their legal guardians and by reviewing hospi-
tal documents.
Statistical analysis was performed using SPSS software 
(SPSS inc., version 20).
This study has been granted an exemption from 
requiring ethics approval as it is an retrospective 
study and all patient information have been directly 
anonymised. The exemption was granted by be eth-
ics committee of the physician Chamber Hamburg, 
Germany.
Results
From 2011 to 2013, 200 cases of malaria were treated at 
the UKE, 90 % of them were due to infection with P. fal-
ciparum. Plasmodium vivax accounted for only one or 
two cases per year, imported from Afghanistan and Benin 
(2011), Pakistan and Brazil (2012) or Vanuatu (2013). In 
2014, a sharp increase was recognized and 23 cases of 
vivax malaria were diagnosed, of which 22 occurred in 
Eritrean refugees and one case in a refugee from Syria. In 
2015, until August, there were 16 cases of vivax malaria, 
15 cases in Eritrean refugees and one case in a return-
ing traveller from Indonesia. One additional case was an 
unspecified tertian malaria from Uganda (Fig. 1).
There was no concomitant increase in P. falciparum 
cases (2011: 59, 2012: 55, 2013: 46, 2014: 57, 2015: 55). 
Therefore, a relative increase of vivax malaria from only 
2 % of all cases in 2013 to 26 % in 2014 and 34 % in 2015 
was observed (Fig. 2).
Of the 37 Eritrean patients seen in the institution 
since 2014 (Fig. 3), 34 were male (92 %), median age was 
19 years (range 12–37 years), and 35 % (13 patients) were 
of minor age (<18). One patient had a mixed infection 
Fig. 1 Number of cases of P. vivax malaria reported at the UKE Hamburg, Germany by country of origin from 2011 to 2014
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with P. falciparum. One additional case, not included in 
the following statistics, had an infection with Plasmodium 
ovale. For 35 out of the 37 P. vivax patients, the date of 
arrival to Germany was known. Of those, all had arrived to 
Germany during the previous 6 months (median 2 weeks, 
range 1–180 days). All reported migration through Ethio-
pia and/or Sudan before embarking from Libya to Europe 
on the “Central Mediterranean Route” [5].
For 25 patients information about previous presump-
tive malaria attacks was available, 22 of these reported 
having had at least one episode of fever during their jour-
ney from Eritrea, 16 received some anti-malarial treat-
ment during their journey. In six cases, a relapse was 
noticed after recent hospitalization and anti-malarial 
therapy in Germany, even though in all of these cases 
subsequent primaquine therapy had been recommended 
upon discharge to prevent further relapses.
Patients were treated with atovaquone/proguanil (30 
cases), artemether-lumefantrine (4 cases) or chloroquine 
(3 cases). For all patients subsequent primaquine therapy 
was recommended. One patient had glucose-6-phosphate 
dehydrogenase (G6PD) deficiency. In 18 cases it was 
possible track down if the therapy with primaquine was 
taken: In 14 of these (78 %) primaquine was administered 
as recommended. The remaining patients were lost to fol-
low up.
Discussion
Until 2013, only very few malaria cases seen at our Uni-
versity Medical Centre were due to infection with P. 
vivax. This changed considerably in 2014, when more 
than a quarter of cases were diagnosed as vivax malaria; 
the trend currently continues in 2015 and was also 
observed on a national level [1]. The increasing num-
ber of malaria cases coincides with increasing numbers 
of asylum seekers from Eritrea [4] and most vivax cases 
occurred in this group. Thus, Eritrea has become the 
most common country of imported malaria cases seen at 
the UKE in Hamburg, in 2014 and 2015.
Data from Sweden, where Eritrean refugees were the 
third largest group of refugees in 2014 also, indicate a 
similar development [6]. Interestingly, data from Tel Aviv 
Fig. 2 Malaria cases stratified by Plasmodium species treated at the UKE: n = 49, 2014: n = 87, 2015: n = 29 (until June 2015 only)
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suggest that a similar phenomenon already took place in 
Israel in 2010 [7], when there were still only small num-
bers of refugees from Eritrea in Germany that did not 
seem to impact malaria epidemiology in the country.
It remains unclear if the infection was acquired at home 
in Eritrea or during the journey. Interestingly, one case 
of tertian malaria was observed, which was microscopi-
cally most likely an infection with P. ovale. Unfortunately, 
a specimen diagnosis by PCR was not possible, since no 
blood sample was left in this case. Another P. ovale infec-
tion imported from East Africa seen at another hospital 
was, however, confirmed by PCR.
Plasmodium falciparum and P. vivax predominate 
in Eritrea (60 and 39  %), Ethiopia (64 and 36  %) and 
Sudan (95 and 5  %, respectively) [8], whereas P. ovale 
is most often seen in travellers and expatriates return-
ing from West Africa. Nevertheless, data published 
in 2013 reported P. ovale infections in neighbouring 
north-west Ethiopia [9], the parasite therefore seems to 
be endemic in the region. West African migrants from 
a region where P. ovale is fairly common and East Afri-
can migrants both use the route via Libya to come to 
Europe [5]. It is, therefore, also possible that a transmis-
sion between migrants may occur in countries like Libya 
where waves of migrating refugees converge and compe-
tent vectors are present.
Furthermore, it is important to note that Anopheles 
species competent for P. vivax transmission are present 
in most European countries, such as Anopheles atropar-
vus in Germany. Thus, the increased introduction of P. 
vivax into Europe poses the risk for local transmission 
and the occurrence of autochthonous malaria, as recently 
reported from Greece [10].
It is of concern that there were a number of relapses of 
vivax malaria in patients with previous inpatient treat-
ment in Germany, despite the fact that subsequent therapy 
with primaquine had been recommended. Primaquine is 
currently not licensed in Germany and has to be ordered 
from abroad. This makes prompt primaquine treatment 
challenging, especially for patients currently seeking asy-
lum who may not have a fixed place of residence.
Conclusion
A steep rise in vivax malaria in was observed at the Uni-
versity Medical Centre Hamburg-Eppendorf Germany 
since May 2014, almost exclusively seen in Eritrean 
refugees. Awareness of possible P. vivax infection in 
this group of patients and correct diagnosis is of major 
importance in order to treat the patients effectively by 
successive primaquine administration. This is of consid-
erable importance to prevent relapses and to minimize 
the risk of local transmission.
Fig. 3 Number of P. vivax cases in newly arrived Eritrean refugees treated at the UKE from January 2013 until June 2014 (n = 32)
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